Article
Immunology
Yuhua Shi, Qian Lv, Mengjie Zheng, Hongxiang Sun, Fushan Shi
Summary: INF39 is a specific inhibitor for NLRP3 inflammasome activation, without affecting other inflammasomes. It exerts its anti-inflammatory effect by inhibiting the interaction of NEK7-NLRP3 and other downstream events.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Review
Pharmacology & Pharmacy
Xu Chen, Dongxing Zhang, Yuping Li, Weixuan Wang, Weijian Bei, Jiao Guo
Summary: Type 2 diabetes and atherosclerosis are being recognized as inflammatory diseases, with Interleukin-1 beta (IL-1 beta) playing a complex role in their progression. The diversity of NLRP3 inflammasome activation modes is a fundamental reason for the intricate effects on disease progression.
PHARMACOLOGICAL RESEARCH
(2021)
Review
Biochemistry & Molecular Biology
Anna Litwiniuk, Wojciech Bik, Malgorzata Kalisz, Agnieszka Baranowska-Bik
Summary: Alzheimer's disease, obesity, and type 2 diabetes mellitus share common features such as chronic inflammation, increased oxidative stress, insulin resistance, and impaired energy metabolism. Adiposity-related inflammatory factors lead to the formation of inflammasome complexes, which can affect neuroinflammatory processes. The abnormal activation of the NLRP3 signaling pathway may link adiposity with cognitive impairment in humans.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Medicine, General & Internal
Iris Maria Nitulescu, George Ciulei, Angela Cozma, Lucia Maria Procopciuc, Olga Hilda Orasan
Summary: The NLRP3 inflammasome plays a crucial role in the pathophysiology and progression of diabetes mellitus, including both type 1 and type 2 diabetes. It triggers chronic inflammation and is associated with the destruction of pancreatic islet cells, insulin resistance, and various complications linked to diabetes.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Cell Biology
Weijia Li, Xibo Zhao, Rujian Zhang, Jiabin Xie, Guangmei Zhang
Summary: This study aims to investigate the role of NLRP3 in cisplatin resistance in ovarian cancer. It was found that NLRP3 is overexpressed in ovarian cancer and is associated with poor survival. Silencing NLRP3 gene can inhibit the malignant process of cisplatin-resistant ovarian cancer cells.
MEDIATORS OF INFLAMMATION
(2023)
Review
Cell Biology
Li-Min Lei, Xiao Lin, Feng Xu, Su-Kang Shan, Bei Guo, Fu-Xing-Zi Li, Ming-Hui Zheng, Yi Wang, Qiu-Shuang Xu, Ling-Qing Yuan
Summary: Exosomes are extracellular vesicles that play a crucial role in delivering signal molecules from donor cells to recipient cells, with a cargo that includes proteins, DNA, and RNA targeting recipient tissues and organs, influencing disease development. Research indicates that exosomes are significant in the development of insulin resistance caused by obesity, showing promise for diagnosis and therapy of insulin resistance.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Yueke Lin, Xiaoting Lv, Caiyu Sun, Yanlin Sun, Min Yang, Dapeng Ma, Weiqiang Jing, Yunxue Zhao, Yeping Cheng, Haocheng Xuan, Lihui Han
Summary: This study reveals a novel regulatory mechanism of NLRP3 via TRIM50 and suggests that modulating TRIM50 might represent a therapeutic strategy for NLRP3-dependent pathologies.
Article
Environmental Sciences
Jingyuan Zhang, Tianming Qiu, Liping Jiang, Ningning Wang, Yuhan Zhu, Rushan Yan, Shengyu Wang, Jie Bai, Xiaoxia Shi, Guang Yang, Xiaofang Liu, Xiaofeng Yao, Xiance Sun
Summary: Arsenic exposure causes hepatic insulin resistance by activating NLRP3 inflammasome and inhibiting glycolysis pathway. NLRP3 inflammasome binds to PKLR, leading to the development of insulin resistance in the liver.
ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY
(2021)
Article
Biochemistry & Molecular Biology
Sushmita Singh, Aditya Sharma, Bhavimani Guru, Shadab Ahmad, Farah Gulzar, Pawan Kumar, Ishbal Ahmad, Akhilesh K. Tamrakar
Summary: Long-term consumption of high fructose diet activates the NLRP3 inflammasome in adipose tissue, leading to inflammation and lipid accumulation, which in turn impairs glucose metabolism and insulin sensitivity.
JOURNAL OF NUTRITIONAL BIOCHEMISTRY
(2022)
Article
Immunology
Shujuan Hu, Yingxing Hu, Peilin Long, Peixiong Li, Ping Chen, Xianwang Wang
Summary: The study found that Tai Chi intervention can reduce body weight, blood pressure, blood glucose, blood lipids, and the expressions of serum inflammatory factors in pre-diabetic patients, thus improving blood glucose, lipid levels, and insulin resistance.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Wanyi Huang, Ziqi Zhang, Yueyang Qiu, Yuan Gao, Yongqiang Fan, Qiang Wang, Qing Zhou
Summary: Implant surgery triggers inflammatory reactions that impact postoperative outcomes. The inflammasome has a crucial role in inflammation, inducing pyroptosis and producing interleukin-1 beta. The activation of the inflammasome in bone healing after implant surgery needs to be studied. Research has focused on metal-induced NLRP3 inflammasome activation due to the prominence of metals as implant materials. This review consolidates knowledge on NLRP3 inflammasome structures, activation mechanisms, and metal-induced NLRP3 inflammasome activation.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Pharmacology & Pharmacy
Isabela Jesus de Deus, Ana Flavia Martins-Silva, Miliane Martins de Andrade Fagundes, Silvia Paula-Gomes, Fernanda Guimaraes Drummond e Silva, Larissa Leandro da Cruz, Aline Rezende Ribeiro de Abreu, Karina Barbosa de Queiroz
Summary: The NLRP3 inflammasome and oxidative stress play important roles in the development of hepatic insulin resistance (hIR). This review discusses the mechanisms of NLRP3 inflammasome activation, including reactive oxygen species (ROS) production and the involvement of oxidized mitochondrial DNA (ox-mtDNA) and thioredoxin interacting protein (TXNIP). Additionally, the inhibitory effect of bioactive compounds on the insulin signaling pathway and the role of microRNAs in improving hIR are also explored. Further research and clinical studies are needed to better understand the mechanisms of action and potential therapeutic applications of these bioactive compounds in hIR.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Endocrinology & Metabolism
Yuwen Wu, Haohua Deng, Jiazhong Sun, Yancheng Xu
Summary: This study investigates the potential role of Nlr family member X1 (NLRX1) in diabetic nephropathy (DN) and the underlying mechanisms. The results show that NLRX1 can attenuate inflammation and prevent kidney injury by inhibiting NOD-like Receptor Family Pyrin Domain Containing 3 (NLRP3) inflammasome in both in vivo and in vitro models. Therefore, NLRX1 may serve as a potent target for preventing the progression of DN through inhibition of NLRP3 inflammasome-dependent inflammation.
JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
(2023)
Article
Biochemistry & Molecular Biology
Jivanka Mohan, Terisha Ghazi, Makabongwe S. S. Mazibuko, Anil A. A. Chuturgoon
Summary: MetS is a non-communicable disease characterized by a cluster of metabolic irregularities. The prevalence of MetS is increasing rapidly in people living with HIV and ARV usage. Insulin resistance is a common characteristic of MetS that leads to the development of T2DM. The progression of insulin resistance is strongly linked to inflammasome activation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Environmental Sciences
Jixin Zhong, Gang Zhao, Sabrina Edwards, Joanne Tran, Sanjay Rajagopalan, Xiaoquan Rao
Summary: This study investigates the role of NLRP3 inflammasome in PM2.5 exposure-induced insulin resistance and explores the underlying mechanisms. The results show that PM2.5 exposure exacerbates insulin resistance and increases IL-1 beta production, and NLRP3 inflammasome plays a critical role in this process.
ENVIRONMENTAL POLLUTION
(2023)
Article
Immunology
Yelei Guo, Beilei Xu, Zhiqiang Wu, Jian Bo, Chuan Tong, Deyun Chen, Jin Wang, Haoyi Wang, Yao Wang, Weidong Han
Summary: Recent studies have shown that UCAR T cells lacking endogenous T cell receptors and beta-2 microglobulin, but engineered with mutant B2M-HLA-E and B2M-HLA-G fusion proteins, are effective in resisting allogeneic NK cell-mediated lysis and have specific anti-tumor activity. Additional experiments, including animal models and clinical trials, are needed to further evaluate the safety and efficacy of these modified UCAR T cells.
EUROPEAN JOURNAL OF IMMUNOLOGY
(2021)
Article
Oncology
Yajing Zhang, Yao Wang, Yang Liu, Chuan Tong, Chunmeng Wang, Yelei Guo, Dongdong Ti, Qingming Yang, Shen Qiao, Zhiqiang Wu, Weidong Han
Summary: A clinical trial of CAR T cell therapy for recurrent/refractory non-Hodgkin lymphoma showed a high overall response rate and progression-free survival, with manageable side effects such as cytokine release syndrome and CAR T cell-related encephalopathy syndrome.
Editorial Material
Immunology
Xiaolei Li, Hanren Dai, Xian Li, Ping Li, Wenbin Qian, Aibin Liang, Weidong Han
CELLULAR & MOLECULAR IMMUNOLOGY
(2022)
Letter
Hematology
Yelei Guo, Chuan Tong, Liping Su, Wenying Zhang, Hejin Jia, Yang Liu, Qingming Yang, Zhiqiang Wu, Yao Wang, Weidong Han
Review
Oncology
Yang Xu, Ping Li, Yang Liu, Dijia Xin, Wen Lei, Aibin Liang, Weidong Han, Wenbin Qian
Summary: This review discusses the rationale behind incorporating epigenetic therapy into immunotherapy, known as epi-immunotherapy. It provides an update on current clinical trials in hematological and solid malignancies and outlines future challenges and strategies in the field of cancer epi-immunotherapy.
CANCER COMMUNICATIONS
(2022)
Article
Hematology
Xin Yan, Deyun Chen, Xinran Ma, Yao Wang, Yelei Guo, Jianshu Wei, Chuan Tong, Qi Zhu, Yuting Lu, Yang Yu, Zhiqiang Wu, Weidong Han
Summary: This study identified and validated the loss of CD58 as a mechanism of immune evasion from CAR T cells. Disruption of CD58 in tumor cells induced suboptimal immunological synapse with CAR T cells, leading to impaired CAR T cell function.
Review
Medicine, General & Internal
Yajing Zhang, Yang Xu, Xiuyong Dang, Zeyu Zhu, Wenbin Qian, Aibin Liang, Weidong Han
Summary: The remarkable improvement of CAR-T cell therapy in the treatment of hematological malignancies relative to traditional approaches has led to the sequential approvals of eight commercial CAR-T products in the past five years. While the productization of CAR-T cells is rapidly expanding their clinical application in real-world patients, the limitations of their clinical efficacy and associated toxicities inspire the further optimization of CAR structure and substantial development of innovative trials. This article summarizes the current status and major progress of CAR-T therapy for hematological malignancies, discusses the factors that may compromise the clinical efficacy of CAR-T cells, such as CAR-T cell exhaustion and loss of antigen, and proposes potential optimization strategies to address the challenges in the field of CAR-T therapy.
CHINESE MEDICAL JOURNAL
(2023)
Article
Biochemistry & Molecular Biology
Zongzhi Liu, Xiang Li, Yibo Gao, Jiejie Liu, Yating Feng, Yang Liu, Junyun Wang, Chunmeng Wang, Dongrui Wang, Jie He, Weidong Han, Qian Mei, Yingli Sun
Summary: The combination of low-dose decitabine and PD-1 antibody treatment improves the complete response rate of cHL patients, indicating the correlation between epigenetic regulation and the clinical response to immunotherapy.
Article
Oncology
Ping Li, Yang Liu, Yun Liang, Jian Bo, Sujun Gao, Yongxian Hu, Yu Hu, He Huang, Xiaojun Huang, Hongmei Jing, Xiaoyan Ke, Jianyong Li, Yuhua Li, Qifa Liu, Peihua Lu, Heng Mei, Ting Niu, Yongping Song, Yuqin Song, Liping Su, Sanfang Tu, Jianxiang Wang, Depei Wu, Zhao Wang, Kailin Xu, Zhitao Ying, Qingming Yang, Yajing Zhang, Fengxia Shi, Bin Zhang, Huilai Zhang, Xi Zhang, Mingfeng Zhao, Weili Zhao, Xiangyu Zhao, Liang Huang, Jun Zhu, Wenbin Qian, Weidong Han, Aibin Liang
Summary: Adoptive cellular immunotherapy with CAR T cells is a promising approach for treating relapsed and/or refractory B-NHL. However, CAR T-cell-associated toxicities can be severe, compromising the survival benefit. Clinical management of these toxicities is crucial, but previous guidelines provide limited recommendations.
CANCER BIOLOGY & MEDICINE
(2023)
Article
Immunology
Yuzhuo Yang, Yajing Zhang, Xiaoyan Xing, Gang Xu, Xin Lin, Yao Wang, Meixia Chen, Chunmeng Wang, Bin Zhang, Weidong Han, Xiaoyu Hu
Summary: Metoprolol, an FDA-approved drug for cardiovascular conditions, may alleviate cytokine release syndrome (CRS) caused by CAR T-cell therapy. It was found that metoprolol blocks IL-6 protein translation rather than IL-6 mRNA expression. Clinical trials have shown that metoprolol has a favorable safety profile in CRS management and does not compromise the efficacy of CAR T-cell therapy.
JOURNAL OF EXPERIMENTAL MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Yao Wang, Chuan Tong, Yuting Lu, Zhiqiang Wu, Yelei Guo, Yang Liu, Jianshu Wei, Chunmeng Wang, Qingming Yang, Weidong Han
Summary: CAR-T cell therapy has become an important treatment option for patients with relapsed/refractory B-cell malignancies, but a significant number of DLBCL patients fail to achieve durable response. This study analyzed the characteristics of pre-manufacture T cells and CAR-T cell products in DLBCL patients and identified the key role of CD8+ stem cell-like memory T cells in achieving durable clinical response. Heterogeneity in the cellular and molecular features of pre-manufacture T cells contributes to the variation in efficacy after CAR-T cell therapy, and loss of CCR7 gene expression and increased expression of activation- and inhibitor-related genes in CD8+ naive-T cell populations may explain the differences in anti-tumor efficacy among patients with different clinical outcomes.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2023)
Article
Hematology
Xiaolei Li, Hanren Dai, Yao Wang, Zhiqiang Wu, Hua Wang, Wenbin Qian, Aibin Liang, Weidong Han
Summary: This paper provides an overview of the current regulatory reforms on clinical cellular therapy in China, emphasizing the need for establishing a legislative system with clear and cohesive policies to promote the use of cellular therapy.
LANCET HAEMATOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Xin Yan, Deyun Chen, Yao Wang, Yelei Guo, Chuan Tong, Jianshu Wei, Yajing Zhang, Zhiqiang Wu, Weidong Han
Summary: Loss of NOXA, a BCL2 family protein, was identified as a key regulator of resistance to CAR T-cell therapy. Low NOXA expression was associated with worse survival in patients with B-cell lymphoma. In vitro and in vivo experiments showed that enhancing NOXA expression using HDAC inhibitors dramatically increased sensitivity of cancer cells to CAR T-cell clearance.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2022)
Review
Oncology
Dongdong Ti, Xin Yan, Jianshu Wei, Zhiqiang Wu, Yao Wang, Weidong Han
Summary: Immunogenic cell death is a regulated form of cell death that activates immune responses in the tumor microenvironment, improving the efficacy of cancer treatment. Inducers of immunogenic cell death enhance the immunogenicity of cancer cells and modulate the tumor microenvironment, amplifying antitumor immune responses.
CHINESE JOURNAL OF CANCER RESEARCH
(2022)
Article
Oncology
Baolin Liu, Xueda Hu, Kaichao Feng, Ranran Gao, Zhiqiang Xue, Sujie Zhang, Yuanyuan Zhang, Emily Corse, Yi Hu, Weidong Han, Zemin Zhang
Summary: In lung cancer patients treated with anti-PD-1, precursor exhausted T cells were found in responders, accumulating through local expansion and clonal revival from peripheral T cells.